$ONC · BeOne Medicines Ltd.
BeOne Medicines reported Q3 FY2026 results: total revenue of $1.89B, up 34% YoY, driven by BRUKINSA global sales of $1.4B (+34%). GAAP diluted EPS per ADS was $3.28 and non-GAAP diluted EPS per ADS was $4.59. The company raised FY2026 total revenue guidance to $6.9B–$7.0B and GAAP operating income to $1.2B–$1.3B.
- Total Q3 revenue $1.89B, up 34% YoY; nine-month revenue $5.11B, up 33%.
- BRUKINSA global Q3 sales $1.4B (+34%); U.S. sales $1.0B (+36%).
- GAAP net income $385M, up 208% YoY; adjusted net income $539M, up 77%.
- FY2026 revenue guidance raised to $6.9B–$7.0B from $6.6B–$6.8B.
- Free cash flow $474M in Q3, up $119M YoY.
Extended-hours last trade $400.01, up +5.88% vs regular close of $377.78, reflecting a positive reaction to the beat and raised guidance.
A 34% revenue beat plus a full-year guidance raise signals accelerating commercial momentum for a $40B oncology leader.
BeOne's BRUKINSA-led hematology franchise continues to outgrow peers, with 34% product growth and expanding operating leverage.
A $22M non-cash intangible asset impairment was recorded on discontinuation of POBEVCY promotion. Guidance assumes November 1, 2026 FX rates and excludes new business development activity.